European Healthcare Expenditure on Pharmaceuticals and Medical Non-Durable Goods by Government Schemes and Compulsory Contributory Health Care Financing Schemes by Country

In 2023, European healthcare expenditure on pharmaceuticals and medical non-durable goods via government schemes varied significantly across countries, with Malta leading at €676.29 per capita, closely followed by Germany, Luxembourg, and Switzerland. Notably, Cyprus experienced a substantial growth rate of 64.48%, while other countries like Greece and Hungary saw declines of -2.75% and -0.46% respectively. Over a five-year period, countries like Lithuania and Malta exhibited remarkable CAGR, indicating strong upward trends in healthcare spending.

For future trends, anticipate continued growth driven by increasing healthcare demands, aging populations, and innovations in pharmaceuticals impacting spending across European nations. Monitoring policy changes and economic conditions will be crucial for forecasting future expenditure shifts in this sector.